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Available online 9 May 2017Objectives:We conducted a population based study aiming at finding predictors of mortality in psychotic disor-
ders and evaluating the extent towhich sociodemographic, lifestyle and health-related factors explain the excess
mortality.
Methods: In a nationally representative sample of Finns aged 30–70 years (n = 5642), psychotic disorders were
diagnosed using structured interviews and medical records in 2000–2001. Information on mortality and causes
of death was obtained of those who died by the end of year 2013. Cox proportional hazards models were used to
investigate the mortality risk.
Results: No people with affective psychoses (n= 36) died during the follow-up, thus the analysis was restricted
to non-affective psychotic disorders (NAP) (n=106). Adjusting for age and sex, NAPwas statistically significant-
ly associatedwith all-causemortality (hazard ratio (HR) 2.99, 95% CI 2.03–4.41) and natural-causemortality (HR
2.81, 95% CI 1.85–4.28). After adjusting for sociodemographic factors, health status, inflammation and smoking,
the HR dropped to 2.11 (95% CI 1.10–4.05) for all-cause and to 1.98 (95% CI 0.94–4.16) for natural-causemortal-
ity. Within the NAP group, antipsychotic use at baseline was associated with reduced HR for natural-cause mor-
tality (HR 0.25, 95% CI 0.07–0.96), and smoking with increased HR (HR 3.54, 95% CI 1.07–11.69).
Conclusions: The elevated mortality risk in people with NAP is only partly explained by socioeconomic factors,
lifestyle, cardio-metabolic comorbidities and inflammation. Smoking cessation should be prioritized in treatment
of psychotic disorders. More research is needed on the quality of treatment of somatic diseases in people with
psychotic disorders.





Schizophrenia shortens the lifespan of those affected by up to 20–
30 years (Olfson et al., 2015; Laursen et al., 2014). The excess mortality
is mainly due to diseases and medical conditions, the leading causes
being cardiovascular diseases, cancer, respiratory diseases and diabetes





suvisaari@thl.fi (J. Suvisaari).Olfson et al., 2015). Studies indicate that during recent decades, the
mortality gap between people with serious mental illness and the gen-
eral population has at best narrowed only by a small amount (Wahlbeck
et al., 2011), or has in fact increased (Saha et al., 2007; Olfson et al.,
2015; Lumme et al., 2016; Osby et al., 2016).
Several factors predispose people with psychotic disorders to an in-
creased risk of somatic diseases. Antipsychotic medication causes
weight gain and increases the risk of metabolic syndrome, type 2 diabe-
tes mellitus (T2DM), and cardiovascular disease (Foley and Morley,
2011). Sedentary lifestyle and poor diet, both common among people
with psychotic disorders, further add to the metabolic burden
(Dipasquale et al., 2013; Stubbs et al., 2016). Low income (McCallum
et al., 2013) and living alone (Koskinen et al., 2007) are associated
with excess mortality in the general population, and these factors may
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Low-grade inflammation associated with schizophrenia (Potvin et al.,
2008; Dickerson et al., 2013; Miller et al., 2014; Fernandes et al.,
2016a) could be a peripheral marker of elevated mortality risk, as it is
in the general population (Emerging Risk Factors Collaboration et al.,
2010).
In people with psychotic disorders, the mortality from medical con-
ditions is disproportionately high compared to morbidity (Crump et al.,
2013a). This applies both to cardiovascular diseases and to cancer
(Kisely et al., 2013). Both under-detection (Crump et al., 2013a) and
poorer treatment (Kisely et al., 2013) of medical conditions contribute.
In this study, we investigated mortality in non-affective psychosis
(NAP) during a 13-year follow-up using data from the nationally repre-
sentative Health 2000 Survey. We aimed to find predictors of mortality
in NAP. Specifically, we wanted to see whether excess mortality in psy-
chotic disorders can be explained by previously known
sociodemographic and health-related factors. Further, we hypothesized
that C-reactive protein (CRP) predictsmortality also in NAP but is not an
independent predictor when somatic risk factors are controlled for.
2. Methods
2.1. Study design
The Finnish Health 2000 Survey (BRIF8901) sample consisted of
8028 persons aged 30 years or older. A nationally representative sample
was achieved using a two-stage stratified cluster sampling procedure.
The data were collected between September 2000 and June 2001. The
survey consisted of an interview, a health examination and a shortened
version of theMunich version of the Composite International Diagnostic
Interview (M-CIDI) (Wittchen et al., 1998). Register information on the
whole sample was collected to supplement interview and health exam-
ination data (Aromaa and Koskinen, 2004).
In the Psychoses in Finland study, we screened persons from the
Health 2000 Survey sample for possible psychotic disorder and
interviewed them using the research version of the Structured Clinical
Interview for DSM-IV (SCID-I) (First et al., 2002). Persons were invited
to participate in the SCID-I interview using the following screening
criteria: (1) self-reported psychotic disorder, (2) a diagnosis of possible
or definite psychotic disorder based on the physician's health examina-
tion, (3) psychotic ormanic symptoms in theM-CIDI interview, (4) hos-
pital treatment of any psychotic disorder according to the Hospital
Discharge Register, (5) entitled to free outpatient antipsychoticmedica-
tion, (6) disability pension due to psychotic disorder, and (7)mood-sta-
bilizing medication use without a diagnosis of epilepsy or other
neurological disease. Detailed description about sensitivity and specific-
ity of these screens is reported in Perala et al. (2007).
The participation rate to the SCID-I was 63.4%. In addition, we ob-
tained all lifetime hospital and outpatient case records from psychiatric
and primary care units for all Health 2000 participants. Using all avail-
able information, J.S., J.P., and S.I.S. made the final DSM-IV based diagno-
ses and assessed whether people had a current psychiatric treatment
contact (Perala et al., 2007).
The Health 2000 Survey and the Psychoses in Finland studywere ap-
proved by the Ethics Committees of the National Public Health Institute
(the National Institute for Health andWelfare since 2009) and the Hos-
pital District of Helsinki and Uusimaa. Participants gave a written in-
formed consent after having received a complete description of the
study.
2.2. Study population
In the analysis, we excluded (1) persons aged 70 years and older to
avoid confounding our analysis with the highmortality of the oldest age
groups and (2) persons with substance-induced psychotic disorders or
psychotic disorders due to a general medical condition. The originalstudy sample included 6334 persons aged under 70 years, from whom
5642 (89.1%) had participated in the Health 2000 study and were
followed up in the current study.Weights were used to correct for non-
response, as described in Section 2.5.
In this study, we investigated people with NAP, including schizo-
phrenia, schizophreniform disorder, schizoaffective disorder, delusional
disorder, brief psychotic disorder and psychotic disorder not otherwise
specified. Descriptive data are reported from people with affective psy-
chosis (bipolar I disorder or major depressive disorder with psychotic
features) as well, but a predictor analysis was not possible due to no
deaths in this group in people aged under 70 years.
2.3. Predictors of mortality
2.3.1. Antipsychotic medication
Participants reported their current medication at baseline and that
information was used to code the antipsychotic medication use. Partic-
ipants had brought their prescriptions or medications to the interview
to assist in recording medication use.
2.3.2. Socioeconomic factors
Marital statuswas coded asmarried or cohabiting, or unmarried (di-
vorced, never-married or widowed) at baseline. The registers of the
Finnish Tax Administration were used to determine family income, ad-
justed for family size and divided into quintiles.
2.3.3. Lifestyle and health variables
Bodymass index (BMI)was calculated asweight (kg) divided by the
square of height (m). Participants were categorized as current smokers
or nonsmokers based on their own report at baseline.
2.3.4. Chronic somatic diseases
T2DM was diagnosed according to the WHO 1999 criteria (World
Health Organization Expert Committee, 1999). The diagnostic proce-
dure for possible or definite coronary heart disease (CHD) based on
health examination, electrocardiogram, and register data as described
in Kattainen et al. (2006).
Diagnosis ofmetabolic syndromewas based on TheNational Choles-
terol Education Program's Adult Treatment Panel III criteria (Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults, 2001).
The detailed diagnostic process for these conditions and for the lab-
oratory and other measures are described in supplementary methods.
2.3.5. Low-grade inflammation
Low-grade inflammation was analyzed using a categorical variable
as measured by the highest quintile of CRP concentration (2.43 mg/L)
as a cut-off.
2.4. Information on mortality and causes of death
Information on mortality up to December 31st 2013 and causes of
deathwere obtained from the Cause of Death statistics kept by Statistics
Finland. The statistics contain data fromdeath certificates completed ei-
ther by the treating physician or by the physician who performed the
autopsy. The medicolegal autopsy rate in Finland is exceptionally high
(Lunetta et al., 2007), and the Cause of Death statistics is considered
reliable.
Causes of death were classified into natural causes (ICD-10 A00–
R99), including alcohol-related diseases and accidental poisoning by al-
cohol (F10, G312, G4051, G621, G721, I426, K292, K70, K852, K860,
O354, P043, Q860, X45), and unnatural causes, including suicide
(X60–X84, Y870) and other unnatural causes (V01–X44, X46–X59,
X85–Y86, Y871–Y89).
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Between-group comparisons of clinical and sociodemographic vari-
ables were performed with Pearson's χ2, the Fisher exact test, the
Student's t-test or the Mann–Whitney U test. P b 0.05 was used to de-
note statistical significance.
We used SUDAAN software, Release 11.0.1, in statistical analysis,
taking into account the two-stage cluster sampling design. Samplingde-
signwas taken into account in all statistical analyses, and post-stratifica-
tion weights were applied to adjust for non-response in the baseline
study. Analyses within the psychosis group, as well as the checking of
the proportional hazards assumption for the survival analysis carried
out in SUDAAN, were conducted using SAS software, Version 9.3 for
Windows.
To investigate the effect of different variables on mortality, seven
Cox regressionmodelswere built using SUDAAN's SURVIVAL procedure.
Allmodelswere adjusted for age and sex.Model I included the diagnosis
of NAP, model II NAP and antipsychotic medication use. Inmodels III-VI,
we added one significant group of explanatory variables tomodel II that
could potentially contribute to the excess mortality in NAP: chronic in-
flammation (CRP) in model III, marital status and income in model IV,
lifestyle-related factors (BMI and smoking) inmodel V, and chronic dis-
eases (T2DM, metabolic syndrome and CHD) in model VI. In model VII,
all these variables were entered simultaneously in the model. For the
final model, we checked the proportional hazards assumption by run-
ning the same model with SAS's PHREG procedure, and the Kolmogo-
rov-type supremum test indicated that the proportional hazards
assumption held for all variables. These analyses were done separately
for all-cause mortality and for mortality from diseases and medical
conditions.
Factors predicting mortality in people with psychotic disorder were
analyzed with Cox's proportional hazards model, using SAS's PHREGTable 1
Demographic and clinical characteristics (weighted prevalences and 95% confidence intervals (C
out psychosis diagnosis at study baseline.
Characteristic Non-affective psychosis (n = 106a), % (95% CI) A
Age
30–40 17.5 (11.4–25.9) 1
N40–50 32.6 (24.3–42.1) 3
N50–60 32.1 (23.9–41.6) 2
N60–70 17.8 (11.3–27.0) 1
Sex
Male 42.5 (32.7–52.9) 6
Female 57.5 (47.2–67.3) 3
Married or cohabiting 33.9b (25.7–43.3) 5
Lowest income quintile 50.5 (40.6–60.4) 2
Antipsychotic medication 58.1 (49.0–66.7) 2
Body mass index
b25 31.2d (23.2–40.4) 2
25–30 27.4d (19.6–36.9) 4
N30 41.4d (32.2–51.3) 2
Smoking 40.0f (30.6–50.2) 2
High C-reactive proteinh 43.6i (32.8–54.9) 1
Coronary heart disease 4.8 (2.1–10.6) 3
Metabolic syndrome 46.4l (35.9–57.3) 2
Type 2 diabetes mellitus 18.0 (11.9–26.3) 2
a Except where otherwise indicated.
b n = 105.
c n = 5483.
d n = 103.
e n = 5470.
f n = 105.
g n = 548.
h Highest C-reactive protein concentration quintile (CRP N 2.43 mg/L).
i n = 87.
j n = 32.
k n = 5097.
l n = 99.
m n = 34.
n n = 5268.procedure. Since therewere only 106 peoplewithNAP, sampling design
was not taken into account in these analyses. The same variables were
used as in model VII for the total sample, with the exception of CHD
due to the small number of cases. This analysis was done separately
for all-cause mortality and for mortality from diseases and medical
conditions.
3. Results
Demographic and clinical characteristics in the NAP group, in the af-
fective psychosis group, and in the group without psychosis diagnosis
are shown in Table 1. In the affective psychosis group, there were no
deaths during the follow-up and thus, in the analysis of predictors of
mortality, we focused on NAP. Among participants with NAP, there
were altogether 25 deaths (Supplementary Table 1). Deaths by natural
causes made up 84% (21/25) of the total number of deaths in the NAP
group, and cancer (32%) and cardiovascular disease (24%) were the
most common causes of death.
In the NAP group, those who died during the follow-up were older,
had a higher prevalence of T2DM, and were more often living alone
than those who survived (Table 2).
Table 3 presents the mortality hazard ratios (HR) from Cox regres-
sion models during the follow-up adjusted with seven different sets of
variables. Diagnosis of NAP was a significant predictor of all-causemor-
tality even after adjusting for all sociodemographic and health-related
variables (HR 2.11, 95% CI 1.10–4.05).
In the Cox model for natural-cause mortality, the mortality HR for
NAP was from 2.0 to 2.8, depending on the adjusting variables (Table
4).When adjusting for all the relevant variables (Model VII), themortal-
ity HR for NAP lost its statistical significance (HR 1.98, 95%CI 0.94–4.16).
In all the othermodels, NAPwas a significant predictor for natural-cause
mortality. Full models are presented in Supplementary Tables 2 and 3.I)) of the non-affective psychosis group, the affective psychosis group and the groupwith-
ffective psychosis (n = 36a), % (95% CI) No psychosis (n = 5500a), % (95% CI)
8.1 (8.9–33.3) 29.1 (27.9–30.3)
9.8 (25.1–56.6) 28.9 (27.7–30.1)
5.8 (14.1–42.3) 26.3 (25.1–27.5)
6.4 (7.6–31.9) 15.7 (14.7–16.8)
3.2 (46.7–77.1) 49.8 (48.5–51.2)
6.8 (22.9–53.3) 50.2 (48.9–51.5)
9.3 (42.5–74.2) 74.2%c (73.0–75.5)
2.0 (11.3–38.4) 18.5 (17.3–19.8)
9.9 (16.3–48.3) 0.7 (0.5–1.0)
5.1 (14.0–40.8) 38.9e (37.6–40.3)
5.9 (31.3–61.4) 39.8e (38.5–41.1)
9.0 (16.1–46.4) 21.3e (20.3–22.4)
9.0 (16.3–46.0) 26.4g (25.3–27.5)
8.4j (8.2–36.1) 19.6k (18.5–20.7)
.1 (0.4–19.2) 5.3 (4.6–6.0)
4.1m (12.4–41.5) 27.6n (26.2–29.0)
.7 (0.4–16.8) 4.2 (3.7–4.7)
Table 2
Comparison of demographic and clinical characteristics between those who died during the follow-up and those who survived in the non-affective psychosis group.
Characteristic Dead % (n = 25/106, 23.6%) Alive % (n = 81/106, 76.4%) Statistics
Sex (% females) 48.0 (12/25) 38.3 (31/81) χ2 = 0.75, p = 0.39
Age at baseline (mean, SD) 55.9, SD 9.3 48.8, SD 10.0 t = −3.13, p = 0.002
Married or cohabiting 16.0 (4/25) 40.0 (32/80) χ2 = 4.87, p = 0.03
Active treatment contact 65.2 (15/23) 74.0 (54/73) χ2 = 0.66, p = 0.42
C-reactive protein (mg/l) (median, min-max) 2.17, 0.00–28.3a 1.47, 0.00–16.0b U = 751.50, p = 0.17
Antipsychotic use 60.0 (15/25) 58.0 (47/81) χ2 = 0.03, p = 0.86
Body mass index (kg/m2) 28.6, SD 5.28c 28.9, SD 6.10d t = 0.22, p = 0.83
Proportion diagnosed with T2DM 36.0 (9/25) 12.3 (10/81) p = 0.014 (Fisher's exact test)
Proportion diagnosed with CHD 4.0 (1/25) 4.9 (4/81) p = 1.000 (Fisher's exact test)
Metabolic syndrome 62.5 (15/24) 41.3 (31/75) χ2 = 3.28, p = 0.07
Smoking 56.0 (14/25) 35.0 (28/80) χ2 = 3.50, p = 0.06
Lowest income quintile 56.0 (14/25) 49.4 (40/81) χ2 = 0.34, p = 0.56
Abbreviations: χ2, Pearson's chi square test; t, Student's t-test; U, Mann-Whitney U test; T2DM, type 2 diabetes mellitus; CHD, coronary heart disease.
a Information available n = 18.
b Information available n = 69.
c Information available n = 24.
d Information available n = 79.
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with reduced HR for natural-cause mortality (HR 0.25, 95% CI 0.07–
0.96), and smoking with increased HR (HR 3.54, 95% CI 1.07–11.69),
whereas none of the variables was a significant predictor of all-cause
mortality (Supplementary Tables 4 and 5). A separate model was not
done for mortality from unnatural causes because of their low frequen-
cy in the NAP group.
4. Discussion
In this study, we found an almost 3-fold increase in themortality HR
for those diagnosed with NAP during a 13-year follow-up compared to
the general population. The HR decreased to 2.1 when adjusting for all
relevant sociodemographic and lifestyle variables and for somatic dis-
eases. The increasedmortality of people diagnosedwith NAPwasmost-
ly due to natural causes. Accidents and suicide accounted for 16% of total
number of deaths in the NAP group. Smoking increased the mortality
HR for natural-cause mortality in the NAP group while antipsychotic
use decreased it.
We observed an increasedmortalityHR in peoplewithNAP in accor-
dance with previous literature (Olfson et al., 2015; Suvisaari et al.,
2013). When smoking, obesity, socioeconomic factors, chronic condi-
tions and inflammation were taken into account, the HR associated
with NAP dropped from three to two, suggesting that these factors ex-
plain some but not all excess mortality related to NAP. Worse quality
of treatment may be one contributing factor. In previous studies,
worse quality of treatment has been particularly evident for cardiovas-
cular diseases and cancer, which were the most common causes of
death in the NAP group. For example, a previous Finnish study found
that patients with NAPwith CHDwere much less likely to receive coro-
nary revascularization than other peoplewith CHD (Manderbacka et al.,
2012). Studies from other countries have found poorer quality of cancer
treatment in people with psychotic disorders (Bergamo et al., 2014;Table 3
Cox proportional hazards model for all-cause mortality in people diagnosed with non-affective
Model Ia Model IIb Model IIIc Model IVd









Abbreviations: HR, hazard ratio; CI, confidence interval; p, p-value.
a Adjusted for sex and age.
b Adjusted in addition for antipsychotic use.
c Adjusted in addition for C-reactive protein concentration.
d Adjusted for (b), marital status and income.
e Adjusted for (b), body mass index and smoking status.
f Adjusted for (b), type 2 diabetes mellitus, metabolic syndrome and coronary heart disease
g Adjusted for all variables in a–f.Ishikawa et al., 2016) and a similar observation has been made in Fin-
land (K. Manderbacka, personal communication). Poor participation in
cancer screenings may be an additional factor contributing to increased
mortality from cancer (Weinstein et al., 2016).
Within the NAP group, smoking was significantly associated with
excess mortality risk, which is consistent with previous studies
(Dickerson et al., 2016; Tam et al., 2016).
The low prevalence of smoking in Finland as compared to several
other countries further stresses its importance for excess mortality. Un-
fortunately, smoking cessation is still often neglected in clinical practice,
although there are effective ways to support quitting (Stubbs et al.,
2015). Our results highlight the importance of smoking prevention
and cessation to decrease the mortality of people with serious mental
illness.
Recentmeta-analyses show that CRP is higher in psychotic disorders
than in the general population, and this has been used as evidence for a
systemic inflammatory disorder (Fernandes et al., 2016a; Fernandes et
al., 2016b). Also in our study, CRP was elevated in the NAP group. Con-
sistentwith previous studies (Emerging Risk Factors Collaboration et al.,
2010) CRP was a risk factor for excess mortality in our sample in the
total population. The NAP group showed a trend towards higher CRP
concentration for those who died during the follow-up. However, CRP
was not an independent predictor of mortality, although the modest
power does not allow us to exclude any independent effect. Given the
sampling at age of 30 or later, the data are not suitable for detecting pos-
sible systemic inflammatory processes at onset of a psychotic disorder.
Antipsychotic treatment at baseline in people with NAP was associ-
ated with lower mortality risk. In our previous study, antipsychotic use
was associated with elevated mortality risk in people who did not have
a psychotic disorder but not in people with psychotic disorder
(Suvisaari et al., 2013). Only about 60% of persons with NAP were
using antipsychotics at baseline, and slightlymore had an active psychi-
atric treatment contact. The low rate of self-reported antipsychotic usepsychosis (n = 106) adjusted with a different set of variables in each model.
Model Ve Model VIf Model VIIg










Cox proportional hazards model for natural-cause mortality in people diagnosed with non-affective psychosis (n = 106) adjusted with a different set of variables in each model.
Model Ia Model IIb Model IIIc Model IVd Model Ve Model VIf Model VIIg
















Abbreviations: HR, hazard ratio; CI, confidence interval; p, p-value.
a Adjusted for sex and age.
b Adjusted in addition for antipsychotic use.
c Adjusted in addition for C-reactive protein concentration.
d Adjusted for (b), marital status and income.
e Adjusted for (b), body mass index and smoking status.
f Adjusted for (b), type 2 diabetes mellitus, metabolic syndrome and coronary heart disease.
g Adjusted for all variables in a–f.
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psychotic disorders (Velligan et al., 2009). While diagnoses of psychotic
disorders were lifetime diagnoses and included disorders that were in
remission and no longer required treatment, treatment drop-outs
were also common (Suvisaari et al., 2009). Therefore, the protective ef-
fect of antipsychotic treatment may indicate the importance of treat-
ment adherence in general.
The main strengths of this study are the large and representative
population-based sample, high participation rate and diagnostic screen-
ing using many sources of information. We had extensive measure-
ments of somatic and sociodemographic factors from the baseline.
Information on causes of death in Finland is reliable.
A limitation of the study is that during the follow-up, we had no in-
formation onmental health, antipsychotic use or other potential factors
affectingmortality. Another limitation is the small sample size in surviv-
al analyses done within the NAP group, which resulted in wide confi-
dence intervals. It was somewhat surprising to recognize that no
deaths were detected within the study period among patients with a
psychotic mood disorder. Previous studies have reported an increased
mortality risk for patients withmood disorders as compared to the gen-
eral population (Harris and Barraclough, 1997; Roshanaei-Moghaddam
and Katon, 2009; Crump et al., 2013b), but to a lesser extent than in
schizophrenia (Chesney et al., 2014; Kessing et al., 2015; Walker et al.,
2015). However, we have previously observed in this sample that in
contrast to NAP, people with affective psychoses did not have elevated
risk of T2DM, metabolic syndrome or CHD (Suvisaari et al., 2007;
Suvisaari et al., 2008; Suvisaari et al., 2010). The difference to other stud-
ies in mood disorders might partly be explained by the long duration of
follow-up (Walker et al., 2015), differences in received somatic treat-
ment (Manderbacka et al., 2012) and the fact that the sampling was
done for people 30 years and older excluding thus those who commit-
ted suicide at earlier phase of illness.
5. Conclusions
People with non-affective psychosis have elevated mortality risk,
which is only partly explained by socioeconomic factors, lifestyle, car-
diometabolic comorbidities and inflammation. Smoking was the single
most important factor contributing to mortality within the NAP group.
More research is needed on the quality of treatment of somatic diseases
in people with psychotic disorders. Since smoking cessation (Stubbs et
al., 2015; Tidey and Miller, 2015) and personalized treatment of diabe-
tes (Larsen et al., 2016) are effective interventions to reduce mortality,
they should be prioritized in the treatment of people with psychotic
disorders.
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